In accordance with Article 13 of Law No. 104-12 on freedom of prices and competition and Article 10 of Decree No. 2-14-652 issued for its implementation, as amended and supplemented, the Competition Council makes available to the public the below “summary of the operation” containing the information provided by the parties.<\/p>\n
This information has been prepared by the notifying parties, who are solely responsible. Any inaccurate or distorted information contained therein does not in any way prejudge the Competition Council’s position on the proposed operation.<\/p>\n
The publication of this press release does not attest to the completeness of the file provided for in Article 9 of Decree No. 2-14-652 issued for the implementation of Law No. 104-12 on freedom of prices and competition, as amended and supplemented.<\/p>\n
Names of the companies and groups concerned:<\/strong><\/p>\n Nature of the operation:<\/strong><\/p>\n Economic sectors concerned:<\/strong><\/p>\n Deadline for interested third parties to submit their observations:<\/strong><\/p>\n NON-CONFIDENTIAL SUMMARY OF THE OPERATION PROVIDED BY THE PARTIES<\/strong><\/p>\n The Competition Council received notification of an economic concentration project concerning the acquisition, by the \u201cMohammed VI Investment Fund\u201d, of joint control of the company \u201cMorocco Biotechnologies\u201d (MARBIO), alongside its historical shareholders, the Moroccan State and the company \u201cBAB Consortium S.A.\u201d, through the acquisition of a 10% stake potentially up to 30% of its share capital and related voting rights, respectively from the company \u201cRecipharm AB\u201d and the Moroccan State.<\/p>\n The \u201cMohammed VI Investment Fund\u201d is a Moroccan joint stock company, established by Law No. 76-20 establishing the Mohammed VI Investment Fund, registered with the Rabat Trade Register under number 149,995, with its registered office at 11, Avenue Bir Kacem, Rabat. Its main purpose is to contribute to financing structuring investment projects, strengthening companies’ capital, and supporting production activities.<\/p>\n The Moroccan State is represented by the Minister of Economy and Finance.<\/p>\n The company \u201cBAB Consortium S.A.\u201d is a Moroccan joint stock company, with a share capital of 10,000,000 dirhams, headquartered at 157, Avenue Hassan II, Casablanca, Morocco, and registered with the Casablanca Trade Register under number 495,717. It was established by the companies \u201cBank of Africa\u201d, \u201cBanque Centrale Populaire\u201d, and \u201cAttijariwafa bank\u201d to participate in the project to create vaccine production capacities in Morocco (\u201cProject Lion 1\u201d). Its activities include the implementation of all industrial projects, trading of all goods, and taking stakes in existing or forming companies.<\/p>\n The company \u201cBank of Africa\u201d is a Moroccan joint stock company, registered with the Casablanca Trade Register under number 27,129 and authorized as a credit institution by Minister of Finance and Investments Order No. 2348-94 of August 23, 1994, with its headquarters at 140, Avenue Hassan II, Casablanca, Morocco. It is a universal multi-business banking group, active particularly in commercial banking, investment banking, specialized financial services such as leasing, factoring, and consumer credit, as well as participatory banking.<\/p>\n The company \u201cBanque Centrale Populaire\u201d is a Moroccan joint stock company, registered with the Casablanca Trade Register under number 28,173 and authorized as a credit institution by Bank Al-Maghrib Governor’s decision No. 28 of October 25, 2010, with its headquarters at 101, Boulevard Mohamed Zerktouni, Casablanca, Morocco. Its main missions include conducting all banking operations for which it is authorized as a credit institution, coordinating the Banque Populaire Group’s policy, and serving as the central banking body for regional popular banks.<\/p>\n The company \u201cAttijariwafa bank\u201d is a Moroccan joint stock company, registered with the Casablanca Trade Register under number 333, with its headquarters at 2, Boulevard Moulay Youssef, Casablanca, Morocco. It is a Moroccan banking group active in retail banking, investment banking, asset management, insurance, and other financial services, with a broad regional presence through subsidiaries in several African countries, as well as in Europe and the Middle East.<\/p>\n The company \u201cMorocco Biotechnologies\u201d (MARBIO) is a Moroccan joint stock company, registered with the Casablanca Trade Register under number 52,205, with its headquarters at 157, Avenue Hassan II, Casablanca, Morocco. It engages in activities across the pharmaceutical and chemical value chain (manufacturing, import, export, distribution, and marketing of drugs, vaccines, medical devices, and raw materials), as well as in intellectual property management and taking stakes in companies in the same sector or related sectors.<\/p>\n Done in Rabat on October 8, 2026<\/p>\n","protected":false},"excerpt":{"rendered":" In accordance with Article 13 of Law No. 104-12 on freedom of prices and competition and Article 10 of Decree No. 2-14-652 issued for its implementation, as amended and supplemented, the Competition Council makes available to the public the below “summary of the operation” containing the information provided by the parties. This information has been prepared by the notifying parties, who are solely responsible. Any inaccurate or distorted information contained therein does not in any way prejudge the Competition Council’s position on the proposed operation. The publication of this press release does not attest to the completeness of the file provided for in Article 9 of Decree No. 2-14-652 issued for the implementation of Law No. 104-12 on freedom of prices and competition, as amended and supplemented. Names of the companies and groups concerned: The acquirer: the \u201cMohammed VI Investment Fund\u201d; The historical shareholders: the Moroccan State, represented by the Minister of Economy and Finance, and the company \u201cBAB Consortium S.A.\u201d, owned by the companies \u201cBank of Africa\u201d, \u201cBanque Centrale Populaire\u201d, and \u201cAttijariwafa bank\u201d; The target: the company \u201cMorocco Biotechnologies\u201d (MARBIO). Nature of the operation: Joint control acquisition. Economic sectors concerned: Market for contract manufacturing services of injectable pharmaceutical products; Vaccine sales market. Deadline for interested third parties to submit their observations: 10 days from the date of publication of this press release, i.e., October 19, 2026. NON-CONFIDENTIAL SUMMARY OF THE OPERATION PROVIDED BY THE PARTIES The Competition Council received notification of an economic concentration project concerning the acquisition, by the \u201cMohammed VI Investment Fund\u201d, of joint control of the company \u201cMorocco Biotechnologies\u201d (MARBIO), alongside its historical shareholders, the Moroccan State and the company \u201cBAB Consortium S.A.\u201d, through the acquisition of a 10% stake potentially up to 30% of its share capital and related voting rights, respectively from the company \u201cRecipharm AB\u201d and the Moroccan State. The \u201cMohammed VI Investment Fund\u201d is a Moroccan joint stock company, established by Law No. 76-20 establishing the Mohammed VI Investment Fund, registered with the Rabat Trade Register under number 149,995, with its registered office at 11, Avenue Bir Kacem, Rabat. Its main purpose is to contribute to financing structuring investment projects, strengthening companies’ capital, and supporting production activities. The Moroccan State is represented by the Minister of Economy and Finance. The company \u201cBAB Consortium S.A.\u201d is a Moroccan joint stock company, with a share capital of 10,000,000 dirhams, headquartered at 157, Avenue Hassan II, Casablanca, Morocco, and registered with the Casablanca Trade Register under number 495,717. It was established by the companies \u201cBank of Africa\u201d, \u201cBanque Centrale Populaire\u201d, and \u201cAttijariwafa bank\u201d to participate in the project to create vaccine production capacities in Morocco (\u201cProject Lion 1\u201d). Its activities include the implementation of all industrial projects, trading of all goods, and taking stakes in existing or forming companies. The company \u201cBank of Africa\u201d is a Moroccan joint stock company, registered with the Casablanca Trade Register under number 27,129 and authorized as a credit institution by Minister of Finance and Investments Order No. 2348-94 of August 23, 1994, with its headquarters at 140, Avenue Hassan II, Casablanca, Morocco. It is a universal multi-business banking group, active particularly in commercial banking, investment banking, specialized financial services such as leasing, factoring, and consumer credit, as well as participatory banking. The company \u201cBanque Centrale Populaire\u201d is a Moroccan joint stock company, registered with the Casablanca Trade Register under number 28,173 and authorized as a credit institution by Bank Al-Maghrib Governor’s decision No. 28 of October 25, 2010, with its headquarters at 101, Boulevard Mohamed Zerktouni, Casablanca, Morocco. Its main missions include conducting all banking operations for which it is authorized as a credit institution, coordinating the Banque Populaire Group’s policy, and serving as the central banking body for regional popular banks. The company \u201cAttijariwafa bank\u201d is a Moroccan joint stock company, registered with the Casablanca Trade Register under number 333, with its headquarters at 2, Boulevard Moulay Youssef, Casablanca, Morocco. It is a Moroccan banking group active in retail banking, investment banking, asset management, insurance, and other financial services, with a broad regional presence through subsidiaries in several African countries, as well as in Europe and the Middle East. The company \u201cMorocco Biotechnologies\u201d (MARBIO) is a Moroccan joint stock company, registered with the Casablanca Trade Register under number 52,205, with its headquarters at 157, Avenue Hassan II, Casablanca, Morocco. It engages in activities across the pharmaceutical and chemical value chain (manufacturing, import, export, distribution, and marketing of drugs, vaccines, medical devices, and raw materials), as well as in intellectual property management and taking stakes in companies in the same sector or related sectors. Done in Rabat on October 8, 2026<\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[352],"tags":[],"class_list":["post-49252","post","type-post","status-publish","format-standard","hentry","category-press-releases"],"acf":[],"yoast_head":"\n\n
\n
\n
\n